Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM1 | Q13255 | 12/20 | 0.81 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.70 |
| ▸ | HPGD | P15428 | 4/20 | 0.70 |
| ▸ | MEN1 | O00255 | 1/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.70 |
| ▸ | GRIA2 | P42262 | 2/20 | 0.65 |
| ▸ | GAA | P10253 | 3/20 | 0.62 |
| ▸ | TSHR | P16473 | 2/20 | 0.62 |
| ▸ | MAPT | P10636 | 2/20 | 0.59 |
| ▸ | TP53 | P04637 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.57 |
| ▸ | THRB | P10828 | 1/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3452157 | 0.91 | GRM1 (0.75) | GRM1ALDH1A1HPGDMEN1KMT2A | |
| SCHEMBL13108879 | 0.90 | GRM1 (0.68) | GRM1ALDH1A1HPGDMEN1KMT2A | |
| SCHEMBL3478613 | 0.90 | GRM1 (0.84) | GRM1ALDH1A1HPGDMEN1KMT2A | |
| SCHEMBL8226585 | 0.90 | GRM1 (0.68) | GRM1ALDH1A1HPGDMEN1KMT2A | |
| SCHEMBL1007269 | 0.90 | GRM1 (1.00) | GRM1ALDH1A1HPGDMEN1KMT2A | |
| SCHEMBL1007297 | 0.90 | GRM1 (0.87) | GRM1ALDH1A1HPGDMEN1KMT2A | |
| SCHEMBL13108851 | 0.89 | GRM1 (0.67) | GRM1ALDH1A1HPGDMEN1KMT2A | |
| SCHEMBL1005578 | 0.89 | GRM1 (0.66) | GRM1ALDH1A1HPGDMEN1KMT2A | |
| SCHEMBL4132111 | 0.88 | ALDH1A1 (0.74) | GRM1ALDH1A1HPGDMEN1KMT2A | |
| SCHEMBL1007789 | 0.88 | GRM1 (0.68) | GRM1ALDH1A1HPGDMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090143411-A1 | Thiophens and Their Use as Anti-Tumor Agents | COMPASS PHARMACEUTICALS LLC (US) | 2009-06-04 | — | — | US | claimed |
| EP-1802634-A2 | THIOPHENS AND THEIR USE AS ANTI-TUMOR AGENTS | Compass Pharmaceuticals LLC (US) | 2007-07-04 | — | — | EP | claimed |
| WO-2006044826-A2 | THIOPHENS AND THEIR USE AS ANTI-TUMOR AGENTS | COMPASS PHARMACEUTICALS LLC (US) | 2006-04-27 | — | — | WO | claimed |
| US-20090143411-A1 | Thiophens and Their Use as Anti-Tumor Agents | COMPASS PHARMACEUTICALS LLC (US) | 2009-06-04 | — | — | US | disclosed |
| EP-1802634-A2 | THIOPHENS AND THEIR USE AS ANTI-TUMOR AGENTS | Compass Pharmaceuticals LLC (US) | 2007-07-04 | — | — | EP | disclosed |
| WO-2006044826-A2 | THIOPHENS AND THEIR USE AS ANTI-TUMOR AGENTS | COMPASS PHARMACEUTICALS LLC (US) | 2006-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143411-A1 | Thiophens and Their Use as Anti-Tumor Agents | TP53, BRDT, VHL | GRM1 4114/4885ALDH1A1 1202/4885HPGD 2732/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.